Role of oral hypoglycemic agents in the management of type 2 diabetes mellitus during Ramadan
Open Access
- 1 January 2012
- journal article
- Published by Medknow in Indian Journal of Endocrinology and Metabolism
- Vol. 16 (4) , 503-7
Abstract
It is obligatory for all adult Muslims to observe fast during the holy month of Ramadan, but sick individuals including those with diabetes mellitus are exempted from the duty of fasting. Specific medical advice must be provided to individual patients concerning the potential risks they must accept if they decide to fast. Any alteration in medications deemed necessary to provide an effective and safe antidiabetic regimen should be instituted well before the start of Ramadan. Diet-controlled patients and those well controlled on insulin sensitizers have low risk of hypoglycemia and may safely fast with some modification in the timing of the doses. Newer generation sulfonylureas (gliclazide MR and glimepiride) have reasonable safety profile during Ramadan fasting and are economical options for a large number of diabetics worldwide, especially in the developing countries; older, long acting sulfonylureas like glibenclamide and chlorpropamide should be avoided during fasting. Oral DPP-IV inhibitors are important substitutes to sulfonylureas for patients with diabetes mellitus during fasting owing to their glucose-dependent mechanism of action, efficacy, and tolerability. This group of drugs causes a moderate A1c reduction, are weight neutral, and have a very low risk of hypoglycemia. Short-acting insulin secretagogues are an option in the subset of fasting diabetic patients who have predominantly post-prandial hyperglycemia.Keywords
This publication has 16 references indexed in Scilit:
- The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trialInternational Journal Of Clinical Practice, 2011
- Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trialDiabetic Medicine, 2008
- Is Ramadan Fasting Safe in Type 2 Diabetic Patients in View of the Lack of Significant Effect of Fasting on Clinical and Biochemical Parameters, Blood Pressure, and Glycemic Control?Clinical and Experimental Hypertension, 2008
- Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes MellitusAnnals of Internal Medicine, 2007
- Recommendations for Management of Diabetes During RamadanDiabetes Care, 2005
- The Efficacy and Safety of Glimepiride in the Management of Type 2 Diabetes in Muslim Patients During RamadanDiabetes Care, 2005
- A Population-Based Study of Diabetes and Its Characteristics During the Fasting Month of Ramadan in 13 CountriesDiabetes Care, 2004
- GUIDE study: double‐blind comparison of once‐daily gliclazide MR and glimepiride in type 2 diabetic patientsEuropean Journal of Clinical Investigation, 2004
- The Role of Sulphonylureas in the Management of Type 2 Diabetes MellitusDrugs, 2004
- Muslims with non-insulin dependent diabetes fasting during Ramadan: treatment with glibenclamide.BMJ, 1993